Champions Oncology Inc. Common Stock (CSBR)
Stock · NASDAQ · Health Care
$4.7as of 10/16/2026
Price chart
Active signals
CSBR Signal Track Record
How signals performed across all stocks →What CSBR's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakout | 25 | -5.7% | 36% | September 18, 2026 |
| Bollinger Band Breakdown | 24 | -1.2% | 50% | September 15, 2026 |
| Volume Spike | 25 | +0.5% | 52% | May 28, 2026 |
| 200-Day Moving Average TouchActive now | 13 | -9.5% | 38% | June 29, 2026 |
| Any 20-session window (baseline) | -1.7% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CSBR
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform. It also offers translational oncology solutions that utilizes its technology platform to provide research service…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 214
- Website
- championsoncology.com
Fundamentals
- 1-day range
- $4.75$4.85
- Market cap
- $72.11M
- P/E (trailing)
- —
- P/E (forward)
- 48.20
- EPS (trailing)
- $-0.08
- Dividend yield
- —
- Beta
- 0.41
- Avg. volume
- 10.9K
How Champions Oncology Inc. Common Stock Makes Money
Where the revenue actually goes — FY2026 annual results
Source: 10-K filed Jul 27, 2026 · via SEC EDGAR / Finnhub
Champions Oncology Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CSBRChampions Oncology Inc. Common Stock$4.7▼ 1.88%Market cap $72.11MP/E —$4.59$8.31
- ELOXEloxx Pharmaceuticals Inc. Common Stock$13.03▼ 4.89%Market cap $71.48MP/E —$0$23.4
- LONALeonaBio Inc. Common Stock$5.2▼ 1.70%Market cap $73.36MP/E —$2.21$14.21
- ATRAAtara Biotherapeutics Inc. Common Stock$9.18▼ 4.87%Market cap $74.33MP/E —$3.92$19.15
- CRDFCardiff Oncology Inc. Common Stock$0.9▼ 7.22%Market cap $74.71MP/E —$0.7566$3.31
- IMAImageneBio Inc. Common Stock$4.04▲ 0.25%Market cap $63.50MP/E —$3.9$9.1
- GNTAGenenta Science S.p.A. American Depositary Shares$0.675▲ 0.90%Market cap $63.16MP/E —$0.55$10
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CSBR Champions Oncology Inc. Common Stock | $72.11M | — | $4.7 | ▼ 1.88% | $4.59$8.31 |
| ELOX Eloxx Pharmaceuticals Inc. Common Stock | $71.48M | — | $13.03 | ▼ 4.89% | $0$23.4 |
| LONA LeonaBio Inc. Common Stock | $73.36M | — | $5.2 | ▼ 1.70% | $2.21$14.21 |
| ATRA Atara Biotherapeutics Inc. Common Stock | $74.33M | — | $9.18 | ▼ 4.87% | $3.92$19.15 |
| CRDF Cardiff Oncology Inc. Common Stock | $74.71M | — | $0.9 | ▼ 7.22% | $0.7566$3.31 |
| IMA ImageneBio Inc. Common Stock | $63.50M | — | $4.04 | ▲ 0.25% | $3.9$9.1 |
| GNTA Genenta Science S.p.A. American Depositary Shares | $63.16M | — | $0.675 | ▲ 0.90% | $0.55$10 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Champions Oncology Q4 2026 Earnings Call Transcriptbenzinga · 10/8/2026
- Champions Oncology Q4 2026 Earnings Call TranscriptBenzinga · 10/8/2026
- Champions Oncology Q3 2026 Earnings Call TranscriptBenzinga · 10/8/2026
- Full Transcript: Champions Oncology Q1 2027 Earnings CallBenzinga · 10/8/2026
- Capitalize on the Global PDX Models Shift: Benchmark Charles River, Crown Bioscience, Champions Oncology, The Jackson Laboratory and Oncodesign to Secure Precision Oncology ROIYahoo · 9/22/2026
- Full Transcript: Champions Oncology Q4 2026 Earnings CallBenzinga · 9/17/2026
- CSBR Stock Slips Post Q1 Earnings Despite Revenue, Margin GrowthYahoo · 9/15/2026
- Champions Oncology Inc (CSBR) (Q1 2027) Earnings Call Highlights: Data Licensing Surge and ...Yahoo · 9/15/2026
- Champions Oncology (CSBR) Q1 2027 Earnings Call TranscriptYahoo · 9/11/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 5.72M
- Total value held
- $32.70M
- Institutional holders
- 23
- Unknown2.42M
- Unknown1.71M
- Unknown319.7K
- Unknown299.5K
- Unknown242.3K
- Unknown145.5K
- Unknown123.9K
- Unknown111.3K
- Unknown77.2K
- Unknown45.9K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Champions Oncology Highlighted in Global PDX Models Shift
Champions Oncology was highlighted in a Yahoo article that discusses the shift toward patient‑derived xenograft (PDX) models in precision oncology. The story compares the company with peers like Charles River, Crown Bioscience, The Jackson Laboratory and Oncodesign, indicating growing industry focus on PDX‑based research. This comparison suggests Champions may benefit from increased demand for its precision oncology solutions. No new financial data were disclosed.
Champions Oncology Highlighted in Global PDX Models Shift. Champions Oncology was highlighted in a Yahoo article that discusses the shift toward patient‑derived xenograft (PDX) models in precision oncology. The story compares the company with peers like Charles River, Crown Bioscience, The Jackson Laboratory and Oncodesign, indicating growing industry focus on PDX‑based research. This comparison suggests Champions may benefit from increased demand for its precision oncology solutions. No new financial data were disclosed.